Market Overview

UPDATE: Intrexon to Acquire Medistem for $26M

Share:
Related XON
Wunderlich Hikes Intrexon To $70, Sees 'Software/Biotech Hybrid' As A Key Strength
Fibrocell and Intrexon Announce IND Filing of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
McKesson (MCK) Tops Q1 Earnings, Ups Fiscal '16 Outlook - Analyst Blog (Zacks)

Intrexon Corporation (NYSE: XON) today announced that it has entered into a definitive agreement to acquire, for approximately $26 million, San Diego-based Medistem, Inc. (OTC: MEDS) a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult stem cells that stimulate new blood vessel formation and are capable of generating different tissues including heart, brain, pancreas, liver, bone, cartilage and lung. Intrexon intends to employ its integrated synthetic biology platforms to engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs.

See full press release

Posted-In: News Guidance Dividends Contracts Management Global

 

Related Articles (MEDS + XON)

Get Benzinga's Newsletters